Caveolin-1 overexpression is associated with simultaneous abnormal expression of the E-cadherin/α-β catenins complex and multiple erbb receptors and with lymph nodes metastasis in head and neck squamous cell carcinomas

Journal of Cellular Physiology

Volumn 227, Issue 9, 2012, Pages 3344-3353

  Masuelli, Laura ^a   Budillon, Alfredo ^b   Marzocchella, Laura ^c   Mrozek, Marie Agnes ^a   Vitolo, Domenico ^a   Di Gennaro, Elena ^b   Losito, Simona ^b   Sale, Patrizio ^d   Longo, Francesco ^b   Ionna, Franco ^b   Lista, Florigio ^e   Muraro, Raffaella ^f   Modesti, Andrea ^c   Bei, Roberto ^c  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d IRCCS SAN RAFFAELE PISANA   (Italy)

^e Army Medical and Veterinary Research Center   (Italy)

^f UNIVERSITY OF CHIETI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA CATENIN; BETA CATENIN; CAVEOLIN 1; EPIDERMAL GROWTH FACTOR RECEPTOR; PLAKOGLOBIN; UVOMORULIN;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; GENE OVEREXPRESSION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LYMPH NODE METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ALPHA CATENIN; BETA CATENIN; CADHERINS; CARCINOMA, SQUAMOUS CELL; CAVEOLIN 1; CELL LINE, TUMOR; CELL MOVEMENT; EPIDERMAL GROWTH FACTOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; HYPOPHARYNGEAL NEOPLASMS; LYMPH NODES; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; RECEPTOR, ERBB-2;

EID: 84862074153     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24034     Document Type: Article

References (78)

1. Anderson RG. 1998. The caveolae membrane system. Annu Rev Biochem 67: 199-225.
2. Bánkfalvi A, Krassort M, Végh A, Felszeghy E, Piffkó J. 2002. Deranged expression of the E-cadherin/beta-catenin complex and the epidermal growth factor receptor in the clinical evolution and progression of oral squamous cell carcinomas. J Oral Pathol Med 31: 450-457.
3. Bei R, Masuelli L, Moriconi E, Visco V, Moretti A, Kraus MH, Muraro R. 1999. Immune responses to all ErbB family receptors detectable in serum of cancer patients. Oncogene 18: 1267-1275.
4. Bei R, Pompa G, Vitolo D, Moriconi E, Ciocci L, Quaranta M, Frati L, Kraus MH, Muraro R. 2001. Co-localization of multiple ErbB receptors in stratified epithelium of oral squamous cell carcinoma. J Pathol 195: 343-348.
5. Bei R, Budillon A, Masuelli L, Cereda V, Vitolo D, Di Gennaro E, Ripavecchia V, Palumbo C, Ionna F, Losito S, Modesti A, Kraus MH, Muraro R. 2004. Frequent overexpression of multiple ErbB receptors by head and neck squamous cell carcinoma contrasts with rare antibody immunity in patients. J Pathol 204: 317-325.
6. Bei R, Mentuccia D, Trono P, Trono P, Masuelli L, Cereda V, Palumbo C, Marzocchella L, Mrozek MA, Pallotta P, Di Lella G, Modesti M, Cerilli M, Frajese GV, Frajese G, Zambruno G, Modesti A. 2006. Immunity to extracellular matrix antigens is associated with ultrastructural alterations of the stroma and stratified epithelium basement membrane in the skin of Hashimotos thyroiditis patients. Int J Immunopathol Pharmacol 19: 661-674.
7. Bei R, Masuelli L, Trono P, Orvietani PL, Losito S, Marzocchella L, Vitolo D, Albonici L, Mrozek MA, Di Gennaro E, Lista F, Faggioni G, Ionna F, Binaglia L, Manzari V, Budillon A, Modesti A. 2007. The ribosomal P0 protein induces a spontaneous immune response in patients with head and neck advanced stage carcinoma that is not dependent on its overexpression in carcinomas. Int J Oncol 31: 1301-1308.
8. Braakhuis BJ, Leemans CR, Brakenhoff RH. 2004. A genetic progression model of oral cancer: Current evidence and clinical implication. J Oral Pathol Med 33: 317-322.
9. Bradford MM. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254.
10. Bruzzese F, Leone A, Rocco M, Carbone C, Piro G, Caraglia M, Di Gennaro E, Budillon A. 2011. HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT. J Cell Physiol 226: 2378-2390.
11. Chen LF, Cohen EE, Grandis JR. 2010. New strategies in head and neck cancer: Understanding resistance to epidermal growth factor receptor inhibitors. Clin Cancer Res 16: 2489-2495.
12. Cianfrocca M, Goldstein LJ. 2004. Prognostic and predictive factors in early-stage breast cancer. Oncologist 9: 606-616.
13. Cohen EE, Rosen F, Stadler WM, Recant W, Stenson K, Huo D, Vokes EE. 2003. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 21: 1980-1987.
14. Du ZM, Hu CF, Shao Q, Huang MY, Kou CW, Zhu XF, Zeng YX, Shao JY. 2009. Upregulation of caveolin-1 and CD147 expression in nasopharyngeal carcinoma enhanced tumor cell migration and correlated with poor prognosis of the patients. Int J Cancer 125: 1832-1841.
15. El-Naaj IA, Leiser Y, Shveis M, Sabo E, Peled M. 2011. Incidence of oral cancer occult metastasis and survival of T1-T2N0 oral cancer patients. J Oral Maxillofac Surg 69: 2674-2679.
16. Erjala K, Sundvall M, Junttila TT, Zhang N, Savisalo M, Mali P, Kulmala J, Pulkkinen J, Grenman R, Elenius K. 2006. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells. Clin Cancer Res 12: 4103-4111.
17. Fedi P, Pierce JH, Di Fiore PP, Kraus MH. 1994. Efficient coupling with phosphatidylinositol 3-kinase, but not phospholipase C gamma or GTP-ase-acting protein, distinguishes ErbB-3 signalling from that of other ErbB/EGFR family members. Mol Cell Biol 14: 492-500.
18. Fiaccavento R, Carotenuto F, Minieri M, Fantini C, Forte G, Carbone A, Carosella L, Bei R, Masuelli L, Palumbo C, Modesti A, Prat M, Di Nardo P. 2005. Stem cell activation sustains hereditary hypertrophy in hamster cardiomyopathy. J Pathol 205: 397-407.
19. Frederick BA, Helfrich BA, Coldren CD, Zheng D, Chan D, Bunn PA, Jr., Raben D. 2007. Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma. Mol Cancer Ther 6: 1683-1691.
20. Galbiati F, Volonte D, Brown AM, Weinstein DE, Ben-Ze'ev A, Pestell RG, Lisanti MP. 2000. Caveolin-1 expression inhibits Wnt/beta-catenin/Lef-1 signaling by recruiting beta-catenin to caveolae membrane domains. J Biol Chem 275: 23368-23377.
21. Haddad Y, Choi W, McConkey DJ. 2009. Delta-crystallin enhancer binding factor 1 controls the epithelial to mesenchymal transition phenotype and resistance to the epidermal growth factor receptor inhibitor erlotinib in human head and neck squamous cell carcinoma lines. Clin Cancer Res 15: 532-542.
22. Ho CC, Huang PH, Huang HY, Chen YH, Yang PC, Hsu SM. 2002. Up-regulated caveolin-1 accentuates the metastasis capability of lung adenocarcinoma by inducing filopodia formation. Am J Pathol 161: 1647-1656.
23. Huber AH, Stewart DB, Laurents DV, Nelson WJ, Weis WI. 2001. The cadherin cytoplasmic domain is unstructured in the absence of beta-catenin. A possible mechanism for regulating cadherin turnover. J Biol Chem 276: 12301-12309.
24. Hung KF, Lin SC, Liu CJ, Chang CS, Chang KW, Kao SY. 2003. The biphasic differential expression of the cellular membrane protein, caveolin-1, in oral carcinogenesis. J Oral Pathol Med 32: 461-467.
25. Jaskolski F, Mulle C, Manzoni OJ. 2005. An automated method to quantify and visualize colocalized fluorescent signals. J Neurosci Meth 146: 42-49.
26. Jeanes A, Gottardi CJ, Yap AS. 2008. Cadherins and cancer: How does cadherin dysfunction promote tumor progression? Oncogene 27: 6920-6929.
27. Jones AS, Cook JA, Phillips DE, Roland NR. 1993. Squamous carcinoma presenting as an enlarged cervical lymph node. Cancer 72: 1756-1761.
28. Joshi B, Strugnell SS, Goetz JG, Kojic LD, Cox ME, Griffith OL, Chan SK, Jones SJ, Leung SP, Masoudi H, Leung S, Wiseman SM, Nabi IR. 2008. Phosphorylated caveolin-1 regulates Rho/ROCK-dependent focal adhesion dynamics and tumor cell migration and invasion. Cancer Res 68: 8210-8220.
29. Kalyankrishna S, Grandis JR. 2006. Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol 24: 2666-2672.
30. Kato K, Hida Y, Miyamoto M, Hashida H, Shinohara T, Itoh T, Okushiba S, Kondo S, Katoh H. 2002. Overexpression of caveolin-1 in esophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage. Cancer 94: 929-933.
31. Kim MM, Califano JA. 2004. Molecular pathology of head and neck cancer. Int J Cancer 112: 545-553.
32. Kinch MS, Clark GJ, Der CJ, Burridge K. 1995. Tyrosine phosphorylation regulates the adhesions of ras-transformed breast epithelia. J Cell Biol 130: 461-471.
33. Knudsen KA, Soler AP, Johnson KR, Wheelock MJ. 1995. Interaction of alpha-actinin with the cadherin/catenin cell-cell adhesion complex via alpha-catenin. J Cell Biol 130: 67-77.
34. Lee CH, Hung HW, Hung PH, Shieh YS. 2010. Epidermal growth factor receptor regulates beta-catenin location, stability, and transcriptional activity in oral cancer. Mol Cancer 9: 64.
35. Lippman SM, Subdo J, Hong WK. 2005. Oral cancer prevention and the evolution of molecular-target drug development. J Clin Oncol 23: 346-356.
36. López-Knowles E, Zardawi SJ, McNeil CM, Millar EK, Crea P, Musgrove EA, Sutherland RL, O'Toole SA. 2010. Cytoplasmic localization of beta-catenin is a marker of poor outcome in breast cancer patients. Cancer Epidemiol Biomarkers Prev 19: 301-309.
37. Lorch JH, Klessner J, Park JK, Getsios S, Wu YL, Stack MS, Green KJ. 2004. Epidermal growth factor receptor inhibition promotes desmosome assembly and strengthens intercellular adhesion in squamous cell carcinoma cells. J Biol Chem 279: 37191-37200.
38. Lu Z, Ghosh S, Wang Z, Hunter T. 2003. Downregulation of caveolin-1 function by EGF leads to the loss of E-cadherin, increased transcriptional activity of beta-catenin, and enhanced tumor cell invasion. Cancer Cell 4: 499-515.
39. Macrinici V, Romond E. 2010. Clinical updates on EGFR/HER targeted agents in early-stage breast cancer. Clin Breast Cancer 10: E38-E46.
40. Makrilia N, Kollias A, Manolopoulos L, Syrigos K. 2009. Cell adhesion molecules: Role and clinical significance in cancer. Cancer Invest 27: 1023-1037.
41. Marzocchella L, Sini V, Buonomo O, Orlandi A, Masuelli L, Bonanno E, Lista F, Turriziani M, Manzari V, Roselli M, Modesti A, Bei R. 2011. Spontaneous immunogenicity of ribosomal P0 protein in patients with benign and malignant breast lesions and delay of mammary tumor growth in P0-vaccinated mice. Cancer Sci 102: 509-515.
42. Masuelli L, Marzocchella L, Focaccetti C, Lista F, Nardi A, Scardino A, Mattei M, Turriziani M, Modesti M, Forni G, Schlom J, Modesti A, Bei R. 2010. Local delivery of recombinant vaccinia virus encoding for neu counteracts growth of mammary tumors more efficiently than systemic delivery in neu transgenic mice. Cancer Immunol Immunother 59: 1247-1258.
43. Masuelli L, Marzocchella L, Quaranta A, Palumbo C, Pompa G, Izzi V, Canini A, Modesti A, Galvano F, Bei R. 2011. Apigenin induces apoptosis and impairs head and neck carcinomas EGFR/ErbB2 signaling. Front Biosci 16: 1060-1068.
44. Méndez E, Fan W, Choi P, Agoff SN, Whipple M, Farwell DG, Futran ND, Weymuller EA, Jr., Zhao LP, Chen C. 2007. Tumor-specific genetic expression profile of metastatic oral squamous cell carcinoma. Head Neck 29: 803-814.
45. Moon C, Chae YK, Lee J. 2010. Targeting epidermal growth factor receptor in head and neck cancer: Lessons learned from cetuximab. Exp Biol Med (Maywood) 235: 907-920.
46. Murase S, Mosser E, Schuman EM. 2002. Depolarization drives beta-catenin into neuronal spines promoting changes in synaptic structure and function. Neuron 35: 91-105.
47. Nakamura E, Sugihara H, Bamba M, Hattori T. 2005. Dynamic alteration of the E-cadherin/catenin complex during cell differentiation and invasion of undifferentiated-type gastric carcinomas. J Pathol 205: 349-358.
48. Niessen CM, Gottardi CJ. 2008. Molecular components of the adherens junction. Biochim Biophys Acta 1778: 562-571.
49. Nohata N, Hanazawa T, Kikkawa N, Mutallip M, Fujimura L, Yoshino H, Kawakami K, Chiyomaru T, Enokida H, Nakagawa M, Okamoto Y, Seki N. 2011. Caveolin-1 mediates tumor cell migration and invasion and its regulation by miR-133a in head and neck squamous cell carcinoma. Int J Oncol 38: 209-217.
50. Orlichenko L, Weller SG, Cao H, Krueger EW, Awoniyi M, Beznoussenko G, Buccione R, McNiven MA. 2009. Caveolae mediate growth factor-induced disassembly of adherens junctions to support tumor cell dissociation. Mol Biol Cell 20: 4140-4152.
51. Papaspyrou G, Werner JA, Dietz A. 2011. Pharmacotherapy for squamous-cell carcinoma of the head and neck. Expert Opin Pharmacother 12: 397-409.
52. Park SS, Kim JE, Kim YA, Kim YC, Kim SW. 2005. Caveolin-1 is down-regulated and inversely correlated with HER2 and EGFR expression status in invasive ductal carcinoma of the breast. Histopathology 47: 625-630.
53. Patlolla JM, Swamy MV, Raju J, Rao CV. 2004. Overexpression of caveolin-1 in experimental colon adenocarcinomas and human colon cancer cell lines. Oncol Rep 11: 957-963.
54. Pelosi G, Scarpa A, Puppa G, Veronesi G, Spaggiari L, Pasini F, Maisonneuve P, Iannucci A, Arrigoni G, Viale G. 2005. Alteration of the E-cadherin/beta-catenin cell adhesion system is common in pulmonary neuroendocrine tumors and is an independent predictor of lymph node metastasis in atypical carcinoids. Cancer 103: 1154-1164.
55. Potempa S, Ridley AJ. 1998. Activation of both MAP kinase and phosphatidylinositide 3-kinase by Ras is required for hepatocyte growth factor/scatter factor-induced adherens junction disassembly. Mol Biol Cell 9: 2185-2200.
56. Prasad CP, Gupta SD, Rath G, Ralhan R. 2007. Wnt signaling pathway in invasive ductal carcinoma of the breast: Relationship between β-catenin, dishevelled and cyclin D1 expression. Oncology 73: 112-117.
57. Rajjayabun PH, Garg S, Durkan GC, Charlton R, Robinson MC, Mellon JK. 2001. Caveolin-1 expression is associated with high-grade bladder cancer. Urology 58: 811-814.
58. Rimm DL, Sinard JH, Morrow JS. 1995. Reduced alpha-catenin and E-cadherin expression in breast cancer. Lab Invest 72: 506-512.
59. Roura S, Miravet S, Piedra J, Garcia de Herreros A, Dunach M. 1999. Regulation of E-cadherin/catenin association by tyrosine phosphorylation. J Biol Chem 274: 36734-36740.
60. Serra M, Scotlandi K. 2009. Caveolins in the development and diseases of musculoskeletal system. Cancer Lett 284: 113-121.
61. Shiozaki H, Kadowaki T, Doki Y, Inoue M, Tamura S, Oka H, Iwazawa T, Matsui S, Shimaya K, Takeichi M, Mori T. 1995. Effect of epidermal growth factor on cadherin-mediated adhesion in a human oesophageal cancer cell line. Br J Cancer 71: 250-258.
62. Sloan EK, Stanley KL, Anderson RL. 2004. Caveolin-1 inhibits breast cancer growth and metastasis. Oncogene 23: 7893-7897.
63. Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Siu LL. 2004. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 22: 77-85.
64. Takahashi K, Suzuki K, Tsukatani Y. 1997. Induction of tyrosine phosphorylation and association of beta-catenin with EGF receptor upon tryptic digestion of quiescent cells at confluence. Oncogene 15: 71-78.
65. Vasioukhin V, Fuchs E. 2001. Actin dynamics and cell-cell adhesion in epithelia. Curr Opin Cell Biol 13: 76-84.
66. Vermorken JB, Herbst RS, Leon X, Amellal N, Baselga J. 2008. Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies. Cancer 112: 2710-2719.
67. Visco V, Bei R, Moriconi E, Gianni W, Kraus MH, Muraro R. 2000. ErbB2 immune response in breast cancer patients with soluble receptor ectodomain. Am J Pathol 156: 1417-1424.
68. Wheeler DL, Dunn EF, Harari PM. 2010. Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol 7: 493-507.
69. Wiechen K, Diatchenko L, Agoulnik A, Scharff KM, Schober H, Arlt K, Zhumabayeva B, Siebert PD, Dietel M, Schäfer R, Sers C. 2001. Caveolin-1 is down-regulated in human ovarian carcinoma and acts as a candidate tumor suppressor gene. Am J Pathol 159: 1635-1643.
70. Williams TM, Medina F, Badano I, Hazan RB, Hutchinson J, Muller WJ, Chopra NG, Scherer PE, Pestell RG, Lisanti MP. 2004. Caveolin-1 gene disruption promotes mammary tumorigenesis and dramatically enhances lung metastasis in vivo. Role of Cav-1 in cell invasiveness and matrix metalloproteinase (MMP-2/9) secretion. J Biol Chem 279: 51630-51646.
71. Wong SC, Lo ES, Lee KC, Chan JK, Hsiao WL. 2004. Prognostic and diagnostic significance of β-catenin nuclear immunostaining in colorectal cancer. Clin Cancer Res 10: 1401-1408.
72. Xia W, Lau YK, Zhang HZ, Xiao FY, Johnston DA, Liu AR, Li L, Katz RL, Hung MC. 1999. Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members. Clin Cancer Res 5: 4164-4174.
73. Yamaguchi H, Takeo Y, Yoshida S, Kouchi Z, Nakamura Y, Fukami K. 2009. Lipid rafts and caveolin-1 are required for invadopodia formation and extracellular matrix degradation by human breast cancer cells. Cancer Res 69: 8594-8602.
74. Yang G, Truong LD, Timme TL, Ren C, Wheeler TM, Park SH, Nasu Y, Bangma CH, Kattan MW, Scardino PT, Thompson TC. 1998. Elevated expression of caveolin is associated with prostate and breast cancer. Clin Cancer Res 4: 1873-1880.
75. Yoo SH, Park YS, Kim HR, Sung SW, Kim JH, Shim YS, Lee SD, Choi YL, Kim MK, Chung DH. 2003. Expression of caveolin-1 is associated with poor prognosis of patients with squamous cell carcinoma of the lung. Lung Cancer 42: 195-202.
76. Zhang H, Su L, Müller S, Tighiouart M, Xu Z, Zhang X, Shin HJ, Hunt J, Sun SY, Shin DM, Chen ZG. 2008. Restoration of caveolin-1 expression suppresses growth and metastasis of head and neck squamous cell carcinoma. Br J Cancer 99: 1684-1694.
77. Zhang ZB, Cai L, Zheng SG, Xiong Y, Dong JH. 2009. Overexpression of caveolin-1 in hepatocellular carcinoma with metastasis and worse prognosis: Correlation with vascular endothelial growth factor, microvessel density and unpaired artery. Pathol Oncol Res 15: 495-502.
78. Zhao X, Ma C, Cai X, Lei D, Liu D, Xu F, Jin T, Liu J, Pan X. 2011. RNA interference of caveolin-1 via lentiviral vector inhibits growth of hypopharyngeal squamous cell carcinoma FaDu cells In Vitro and In Vivo. Asian Pac J Cancer Prev 12: 397-401.